Abishai Financial Asia: Apotex Moves Toward Public Offering

Generic-drug maker Apotex lines up a Toronto Stock Exchange flotation that could reawaken Canada's IPO pipeline, with private equity retaining control and banks building a syndicate as institutions seek defensives and firmer pricing discipline.
Image: https://www.abnewswire.com/upload/2026/02/e6c393dd40bbf7ae9a7e1d784e3f5482.jpg

Abishai Financial Asia Pte. Ltd. is tracking Apotex Inc.'s move towards a Toronto public offering in the current quarter, a deal targeting up to $730 million in proceeds and putting a sizeable Canadian generic-drug platform back in front of equity investors. The latest full-year disclosure points to about $2.1 billion of revenue, with the core generic franchise expanding 12% over the prior financial year.

For Daniel Coventry, Director of Private Equity at Abishai Financial Asia Pte. Ltd., the flotation is "a live test of whether public markets will back defensive healthcare cash flows while demanding clearer visibility on pricing power and supply resilience". With few large healthcare listings over several years, the transaction sits as a read-through on risk appetite at a time when higher funding costs keep investors selective.

The proposed structure centres on a minority float, leaving SK Capital Partners with control and sharpening the focus on valuation discipline. The sponsor's entry valuation, estimated at about $2.2 billion to $2.9 billion for the current ownership cycle, sets a reference point for the bookbuild, while RBC Capital Markets, Jefferies Financial Group and TD Securities prepare the syndicate to tap Canadian and cross-border demand. Coventry views the setup as "a way to broaden ownership without diluting operational accountability".

Operational scale is part of the pitch, with the latest company snapshot indicating about 6,000 employees and a portfolio of more than 550 products across prescription, over-the-counter and biosimilar categories. Expansion spending also remains central, including a Mississauga manufacturing site budgeted at about $225.2 million and scheduled to move towards commissioning in the next operating cycle. Abishai Financial Asia flags the sequencing of that build-out alongside portfolio additions, including a vitamins and supplements business that, in its current range, offers about 445 products through roughly 3,400 retail outlets.

Management messaging emphasises earnings momentum, with net income projected to grow about 15% over the next two years as efficiency gains and mix shift take hold. The regulatory moat features heavily as well; as of the latest public filings, Apotex holds FDA approval for more than 230 abbreviated new drug applications, equating to about one approval every nine days over the last two years. Coventry's view is that "execution on capacity and approvals is what turns a generic pipeline into investable visibility".

International footprint adds optionality, with current expansion plans including a $175 million Florida site intended to strengthen domestic US production, alongside Mexican facilities targeting about 74 million units of annual output. Company projections point to about $811 million of economic impact over the coming four quarters from the Mexico operations, while the most recent full-year export data show Mexico shipping 165 pharmaceuticals classified as critical by US authorities and generating more than $2.4 billion in cross-border flows.

Investors also weigh structural pressure points that define the sector. Industry pricing datasets show average generic prices sliding about 58% over the last eight completed years of available data, and market monitors flag sudden price moves in roughly 17% of products within recent multi-year samples. The latest procurement snapshots point to three wholesale consortia controlling around 90% of generic purchasing volumes, and expenditure breakdowns indicate manufacturers capture about 36% of spending on their products versus about 76% for branded peers. Coventry characterises the equation as "a concentrated buyer market where risk controls and product selection matter as much as scale".

As marketing gathers pace, Abishai Financial Asia expects the offering to act as a bellwether for whether Toronto can price a sizeable healthcare float without relying on deep discounts, and for whether global investors re-enter Canada's pipeline in meaningful size. Coventry points to "pricing discipline, credible ramp-up and governance that keeps risk measurable" as the questions that set demand and shape the next wave of listings.

Abishai Financial Asia at a Glance

Abishai Financial Asia Pte. Ltd. (UEN: 201016239E) is a Singapore asset manager founded in 2010, positioning itself as a research-led partner for capital allocation decisions.

*
Investment approach: The firm targets risk-aware compounding in public markets through active equity selection, bottom-up research and disciplined rebalancing, supported by overlay tools that aim to improve resilience and capital efficiency, including systematic tilts, opportunistic hedging and drawdown-aware controls.

*
Governance and risk: Portfolio construction applies macro-aware risk budgets with explicit limits, concentration and exposure guardrails, liquidity filters and stress testing, alongside transparent attribution and ongoing monitoring with clear commentary.

*
Sustainability: ESG considerations are integrated through sector and issuer assessments, engagement expectations and governance screens, embedded where financially material across the investment lifecycle.

*
Access: The firm is evaluating compliant product wrappers and distribution routes that, subject to suitability criteria, may expand selected solutions to retail-qualified investors over time.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans, and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Abishai Financial Asia Pte. Ltd
Contact Person: Peng Joon
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=abishai-financial-asia-apotex-moves-toward-public-offering]
Country: Singapore
Website: https://abishai.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.